What Does "staying Well" After Depression Mean? Chronic Low Grade Symptomatology After Treatment for Depression is Common

Overview

Journal J Affect Disord

Date 2022 Aug 27

PMID 36029878

Authors

Marlene V Strege

John A Richey

Greg J Siegle

Affiliations

Soon will be listed here.

Abstract

Background: Persistent low grade depression symptoms are common and impairing in major depressive disorder (MDD) yet rarely reported in treatment follow-up studies (Judd et al., 1998a; Kennedy et al., 2004), suggesting that extant sustained remission rates may not reflect this important clinical feature. Furthermore, no long-term MDD treatment follow-up study has reported on quality of life ratings across functioning levels and years throughout the follow-up period, thus the severity, breadth, and persistence of functional impairment remain unclear. Accordingly, the current study evaluated the course of MDD with consideration of low grade depressive symptomatology and holistic features (e.g., quality of life).

Methods: We report long-term (9-14 years) follow-up data from individuals with MDD (N = 37) who underwent either Cognitive Therapy (CBT) or a course of selective serotonin reuptake inhibitor (SSRI) treatment. Patients provided retrospective reports of depression symptoms and quality of life in the years following treatment.

Results: Chronic depression symptoms (most often mild in severity) and decreased quality of life in multiple domains are frequent and suggest poorer sustained remission rates than previously observed in the literature.

Limitations: Study limitations include small sample size recruited via convenience sampling methods.

Conclusions: Findings support a conceptualization of depression recovery that entails persistent symptoms and vulnerabilities. Clinical recommendations are provided for discussing these features of depression recovery with patients.

Citing Articles

Anti-stigmatizing: a collaborative autoethnography on recovery from depression.

Zhu D, Lyu K Front Psychiatry. 2024; 15:1360967.

PMID: 38690206 PMC: 11059567. DOI: 10.3389/fpsyt.2024.1360967.

Amygdala real-time fMRI neurofeedback upregulation in treatment resistant depression: Proof of concept and dose determination.

Compere L, Siegle G, Lazzaro S, Riley E, Strege M, Canovali G Behav Res Ther. 2024; 176:104523.

PMID: 38513424 PMC: 10999329. DOI: 10.1016/j.brat.2024.104523.

Residual symptoms following electroconvulsive therapy: A retrospective cohort study.

Hart K, McCoy Jr T, Henry M, Seiner S, Luccarelli J J Affect Disord. 2023; 341:374-378.

PMID: 37661058 PMC: 10530260. DOI: 10.1016/j.jad.2023.08.135.

Trying to name what doesn't change: Neural nonresponse to Cognitive Therapy for depression.

Strege M, Richey J, Siegle G Psychol Med. 2023; 54(1):136-147.

PMID: 37191029 PMC: 10651800. DOI: 10.1017/S0033291723000727.

References

Guidi J, Tomba E, Fava G . The Sequential Integration of Pharmacotherapy and Psychotherapy in the Treatment of Major Depressive Disorder: A Meta-Analysis of the Sequential Model and a Critical Review of the Literature. Am J Psychiatry. 2015; 173(2):128-37. DOI: 10.1176/appi.ajp.2015.15040476. View

Fava G, Grandi S, Zielezny M, CANESTRARI R, Morphy M . Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry. 1994; 151(9):1295-9. DOI: 10.1176/ajp.151.9.1295. View

Brunello N, Akiskal H, Boyer P, Gessa G, Howland R, Langer S . Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. J Affect Disord. 1999; 52(1-3):275-90. DOI: 10.1016/s0165-0327(98)00163-3. View

Frank E, Prien R, Jarrett R, Keller M, Kupfer D, Lavori P . Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991; 48(9):851-5. DOI: 10.1001/archpsyc.1991.01810330075011. View

Ten Doesschate M, Koeter M, Bockting C, Schene A . Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord. 2009; 120(1-3):126-32. DOI: 10.1016/j.jad.2009.04.026. View

Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62. PMC: 495331. DOI: 10.1136/jnnp.23.1.56. View

Woo J, Jeon H, Noh E, Kim H, Lee S, Lee K . Importance of remission and residual somatic symptoms in health-related quality of life among outpatients with major depressive disorder: a cross-sectional study. Health Qual Life Outcomes. 2014; 12:188. PMC: 4280041. DOI: 10.1186/s12955-014-0188-y. View

Endicott J, Nee J, Harrison W, Blumenthal R . Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993; 29(2):321-6. View

Kocsis J, Schatzberg A, Rush A, Klein D, Howland R, Gniwesch L . Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry. 2002; 59(8):723-8. DOI: 10.1001/archpsyc.59.8.723. View

10.

Papakostas G, Petersen T, Mahal Y, Mischoulon D, Nierenberg A, Fava M . Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004; 26(1):13-7. DOI: 10.1016/j.genhosppsych.2003.07.004. View

11.

IsHak W, Greenberg J, Balayan K, Kapitanski N, Jeffrey J, Fathy H . Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry. 2011; 19(5):229-39. DOI: 10.3109/10673229.2011.614099. View

12.

Beck A, Crain A, Solberg L, Unutzer J, Glasgow R, Maciosek M . Severity of depression and magnitude of productivity loss. Ann Fam Med. 2011; 9(4):305-11. PMC: 3133577. DOI: 10.1370/afm.1260. View

13.

Guidi J, Fava G . Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020; 78(3):261-269. PMC: 7689568. DOI: 10.1001/jamapsychiatry.2020.3650. View

14.

Hays R, Wells K, Sherbourne C, Rogers W, Spritzer K . Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry. 1995; 52(1):11-9. DOI: 10.1001/archpsyc.1995.03950130011002. View

15.

Angermeyer M, Holzinger A, Matschinger H, Stengler-Wenzke K . Depression and quality of life: results of a follow-up study. Int J Soc Psychiatry. 2002; 48(3):189-99. DOI: 10.1177/002076402128783235. View

16.

Judd L, Akiskal H, Maser J, Zeller P, Endicott J, Coryell W . A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998; 55(8):694-700. DOI: 10.1001/archpsyc.55.8.694. View

17.

Fava G, Tomba E . New modalities of assessment and treatment planning in depression: the sequential approach. CNS Drugs. 2010; 24(6):453-65. DOI: 10.2165/11531580-000000000-00000. View

18.

Horn M, Scharer L, Walser S, Biedermann C, Walden J . Comparison of long-term monitoring methods for bipolar affective disorder. Neuropsychobiology. 2002; 45 Suppl 1:27-32. DOI: 10.1159/000049258. View

19.

Jha M, Minhajuddin A, Thase M, Jarrett R . Improvement in self-reported quality of life with cognitive therapy for recurrent major depressive disorder. J Affect Disord. 2014; 167:37-43. PMC: 4119295. DOI: 10.1016/j.jad.2014.05.038. View

20.

Tranter R, ODonovan C, Chandarana P, Kennedy S . Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci. 2002; 27(4):241-7. PMC: 161658. View